Legal and Regulatory Update
Journal of Commercial Biotechnology (2009) 15, 272–280. doi:10.1057/jcb.2009.15
Legal and Regulatory Update
ReedSmith
Content is compiled and written by Reed Smith
With Lawyers from coast-to-coast in the United States, in the United Kingdom, continental Europe, Asia and the Middle East, Reed Smith provides its clients with seamless services across the world.
Reed Smith counsel 28 of the top 30 U.S. banks and 10 of the world's 12 largest pharmaceutical companies. Our Life Sciences Team includes more than 200 lawyers and health care professionals throughout our offices.
Our Life Sciences Team combines its knowledge of the health care industry, life science product development and management requirements, regulatory demands, and litigation risks, to serve clients who develop and market drug, device, diagonastic, and biotechnology products and services. Our product liability lawyers apply their success in the courtroom to help companies assess risks up front and avoid litigation. Our regulatory lawyers advise clients on how to create the most efficient pathway through product approval and reimbursement, and across the entire product life cycle. Our in-depth knowledge of the life sciences industry enables us to provide clients with counsel tailored to their specific operational workings and strategic business goals
This section is intended to be a synopsis of recent legal developments and is not intended to be exhaustive. If any issue referred to in this section to be relied upon, specific advice should be sought. Please contact:
John Wilkinson
Reed Smith LLP
The Broadgate Tower
20 Primrose Street
London EC2A 2RS
Tel: +44 (0)20 3116 3640
Fax: +44 (0)20 3116 3999
Email: jwilkinson@reedsmith.com
